Analyzing BioAmber (BIOA) and Its Rivals
BioAmber (NYSE: BIOA) is one of 52 publicly-traded companies in the “Specialty Chemicals” industry, but how does it compare to its competitors? We will compare BioAmber to similar businesses based on the strength of its profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.
Insider & Institutional Ownership
37.4% of BioAmber shares are held by institutional investors. Comparatively, 70.0% of shares of all “Specialty Chemicals” companies are held by institutional investors. 8.3% of BioAmber shares are held by insiders. Comparatively, 7.1% of shares of all “Specialty Chemicals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a breakdown of current ratings and recommmendations for BioAmber and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioAmber currently has a consensus target price of $3.00, indicating a potential upside of 568.15%. As a group, “Specialty Chemicals” companies have a potential upside of 3.82%. Given BioAmber’s higher probable upside, equities research analysts plainly believe BioAmber is more favorable than its competitors.
Volatility and Risk
BioAmber has a beta of 2.7, indicating that its share price is 170% more volatile than the S&P 500. Comparatively, BioAmber’s competitors have a beta of 1.58, indicating that their average share price is 58% more volatile than the S&P 500.
This table compares BioAmber and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares BioAmber and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|BioAmber||$10.54 million||-$24.98 million||-0.56|
|BioAmber Competitors||$1.95 billion||$301.80 million||16.27|
BioAmber’s competitors have higher revenue and earnings than BioAmber. BioAmber is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
BioAmber competitors beat BioAmber on 9 of the 12 factors compared.
BioAmber Company Profile
BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.
Receive News & Ratings for BioAmber Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAmber Inc. and related companies with MarketBeat.com's FREE daily email newsletter.